|
121 |
HLA DR-directed bispecific single-chain Fv antibodies for lymphoma therapy
Enthalten in Cancer cell international Bd. 4, 1.7.2004, Nr. 1, date:7.2004: 1
|
|
|
|
122 |
IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern
Enthalten in Nature Communications Bd. 13, 3.10.2022, Nr. 1, date:12.2022: 1-15
|
|
|
|
123 |
Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease
Enthalten in Cancer chemotherapy and pharmacology Bd. 46, Nr. 1, date:7.2000: S33-S36
|
|
|
|
124 |
Immunotherapy using bispecific T cell engager (BiTE®) antibodies: preclinical and clinical experience in acute leukemia
Enthalten in Journal for ImmunoTherapy of Cancer Bd. 2, 6.11.2014, Nr. 3, date:12.2014: 1
|
|
|
|
125 |
Improving outcomes with anti-BCMA bispecific antibodies with attention to infection
Enthalten in Blood cancer journal Bd. 14, 8.7.2024, Nr. 1, date:12.2024: 1-3
|
|
|
|
126 |
Kinetics study of the natural split Npu DnaE intein in the generation of bispecific IgG antibodies
Enthalten in Applied microbiology and biotechnology Bd. 106, 9.12.2021, Nr. 1, date:1.2022: 161-171
|
|
|
|
127 |
Mechanisms of T-lymphocyte activation and cytotoxicity against human tumors induced by bispecific antibodies
Enthalten in Journal of cancer research and clinical oncology Bd. 121, Nr. 1, date:1.1995: A8
|
|
|
|
128 |
Predictive factors and nomogram for the risk of cytokine release syndrome with anti-CD3 × CD20 bispecific antibodies for Chinese patients
Enthalten in Cancer immunology immunotherapy Bd. 74, 4.6.2025, Nr. 7, date:7.2025: 1-10
|
|
|
|
129 |
Preparation and characterization for bispecific antibodies of anti-CD3 X anti-idiotype to B cell lymphocytic leukemia
Enthalten in Current medical science Bd. 19, 1.9.1999, Nr. 3, date:9.1999: 166-169
|
|
|
|
130 |
Pretreatment blast-to-lymphocyte ratio as a prognostic marker for CD19/CD3-bispecific T cell-engaging antibodies (blinatumomab) treatment against relapsed or refractory B-precursor acute lymphoblastic leukemia
Enthalten in Cancer immunology immunotherapy Bd. 72, 7.8.2023, Nr. 11, date:11.2023: 3861-3865
|
|
Administration
